Boule Diagnostics AB has won a significant share of public tenders for a total of 329 hematology systems in Mexico in partnership with its Mexican distributors. The instruments will be delivered at the end of the second quarter and beginning of third quarter 2016. Some smaller follow-up orders are expected during the third quarter. The purchasing organisations have been IMSS (Instituto Mexicano del Seguro Social), the largest and most important public health system in the country, and ISSSTE (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado), the second largest public system in charge of providing health services to government employees.
A total of 118 systems will be placed with IMSS blood bank units in different parts of Mexico. These customers represent 50 per cent of the total blood bank market in the country and Boule will by this tender become the market leader for hematology instruments for blood banks in Mexico.
The remaining 211 units will be placed with primary care labs and hospitals (medical care facilities) all around Mexico.
“Our success in Mexico continues. The decision to open up a sales office in the country in 2013 has proven to be correct. The reason that we managed to win these big tenders is the high quality of our products combined with competent local distributors. We are especially pleased with the break-through in the Mexican blood bank market, a market where we think we can expand our market share globally.”, says Ernst Westman, President and CEO, Boule Diagnostics.
For more information, please contact: Ernst Westman, President and CEO, Boule Diagnostics AB, phone +46 708-60 88 63
About Boule Diagnostics AB (publ) Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. www.boule.se
The information in this press release is such that Boule Diagnostics AB must disclose it in accordance with the Securities Market Act and/or the Financial Instruments Trading. The information was submitted for publication in Swedish at 8:00 am (CET), June 13, 2016.